



API removal with advanced wastewater treatment techniques

Ulf Mieke

Berlin Centre of Competence for Water (KWB)

CWPharma project's final seminar, 18. 11. 2020



Advanced wastewater treatment for API elimination

- Focus of conventional WWTPs: C, N and P reduction
- Some active pharmaceutical ingredients (APIs) are biodegradable and, thus, are also removed at WWTPs (e.g. ibuprofen, metformin)
- Persistent APIs such as carbamazepine and diclofenac require an advanced wastewater treatment. Well known technical measures are:

Ozonation




Powdered activated carbon (PAC)



Ganular activated carbon (PAC)



Overview on CWPharma study sites



Helsinki (FI):
- Powdered activated carbon
- Small, pilot scale


Kalundborg (DK):
large scale ozonation
- $Q_{max} = 1200 \text{ m}^3/\text{h}$
- $m_{\text{O}_3, \text{max}} = 180 \text{ kgO}_3/\text{h}$
-> $D_{\text{calc}, Q_{\text{max}}} = 150 \text{ mgO}_3/\text{L}$

Linköping (SE):
large scale ozonation
- $Q_{max} = 3000 \text{ m}^3/\text{h}$
- $m_{\text{O}_3, \text{max}} = 20 \text{ kgO}_3/\text{h}$
-> $D_{\text{calc}, Q_{\text{max}}} = 6.7 \text{ mgO}_3/\text{L}$

Berlin/Schönerlinde (DE):
Pilot scale ozonation
- $Q_{max} = 15 \text{ m}^3/\text{h}$
- $m_{\text{O}_3, \text{max}} = 0.15 \text{ kgO}_3/\text{h}$
-> $D_{\text{calc}, Q_{\text{max}}} = 10 \text{ mgO}_3/\text{L}$



Impact of ozonation on APIs



Ozonation process


applied ozone dose (mgO₃/L)





DOC (mg/L)

Nitrite (mg-N/L)



Water quality

Impact of ozonation on risk quotient (WWTP Linköping)







Usage of surrogates for process control and monitoring



- API elimination can be monitored by using surrogate parameters (e.g. UVA_{254} reduction or fluorescence) – online or offline.
- Surrogate parameters can also be used for process control to adapt the dosage, but practical implementation sometimes tricky → local assessment of need vs. advantages

Usage of ecotoxicological test systems

17 ecotoxicological tests were performed by IOS (PL), LIAE (LV), and UBA (DE)
→ many of them showed no (systematic) effect at an enrichment factor of 10



Also positive impacts on *Aliivibrio fischeri* bioluminescence

→ Biological post-treatment is needed

Impact of post-treatment

WWTP Kalundborg

<i>Mutagenicity</i>	Ozonation	MBBR
Ames (TA1535, -S9)	→ / ↑	→ / ↓
Ames (TA1535, +S9)	→ / ↓	→
Ames (YG7108, -S9)	→	→

<i>APIs</i>	Ozonation	MBBR
Benzotriazol	↓	→
Gabapentin	↓	→
Metoprolol	↓	→

<i>Transformation products</i>	Ozonation	MBBR
Diclofenac 2,5-Quinon imine	↑	↓ ¹
Tramadol N-Oxid	↑	→
Venlafaxin-N-Oxid	↑	→

WWTP Berlin

Ozonation	S/BAC	S/A	GAC	CW
→	→ / ↓	→ / ↓	→ / ↓	→ / ↓
→ / ↑	→ / ↓	→ / ↓	→ / ↓	→ / ↓
↑	↓	↓	↓	↓

Ozonation	S/BAC	S/A	GAC	CW
↓	↓	→	↓	→
↓	→	→	→	↑
↓	↓	→	↓	→

Ozonation	S/BAC	S/A	GAC	CW
↑	↓	↓	↓	→
↑	→	→	↓	↓
↑	→	→	↓	↓


Legend for APIs and transformation products:
 ↑ = increase of concentration by more than 25%
 → = change of concentration less than 25%
 ↓ = decrease of concentration by more than 25%

¹ single measurement


Bromate formation by ozonation

Bromate drinking water limit (e.g. in Germany) = 10 µg/L

Proposed chronic quality standard for bromate = 50 µg/L¹



➔ Not critical







➔ High bromate formation due to elevated bromide level

➔ Relevant bromide sources: industrial wastewater and sea water intrusion into the canalisation

API elimination at moving bed biofilm reactors

half-life times (DT_{50} in hours, lab-scale tests)



Different MBBR feeding strategies were tested by AU:

- Intermittent feeding
- 12 different treatments
 - 2 days feast, 2-12 days famine
 - One reactor only on famine

Half-life times $\approx 1 - 100$ hours

Impact of existing MBBRs is expected to be low for most APIs, due to low HRT (1 - 2 h)



PAC-trials at WWTP Viikinmäki (FI)

→ Focus: PAC retention from treated wastewater


Microsieve



Cloth filter



ACTIFLO® CARB



Insufficient PAC retention with microsieve
→ risk of PAC entry into aquatic environment

Read also publications from WP3

Reports are available at:
<https://www.cwpharma.fi/en-US/Publications>



CWPharma
CLEAR WATERS FROM PHARMACEUTICALS

Evaluation and experiences of full-scale ozonation followed by MBBR post-treatment and comparison with previous pilot tests

GoA3.1: Pharmaceutical removal at full scale

August 2020



KOMPETENZENTRUM WasserBerlin



CWPharma
CLEAR WATERS FROM PHARMACEUTICALS


Evaluation and experiences of full-scale ozonation followed by MBBR post-treatment at Kalundborg wastewater treatment plant

GoA3.2: Flexible use of existing infrastructure

November 2020



KOMPETENZENTRUM WasserBerlin




CWPharma
CLEAR WATERS FROM PHARMACEUTICALS




Impact of ozonation and post-treatment on ecotoxicological endpoints, water quality, APIs and transformation products

GoA3.3: Comparison of post-treatment options

August 2020



KOMPETENZENTRUM WasserBerlin





CWPharma
CLEAR WATERS FROM PHARMACEUTICALS

Guideline for advanced API removal


November 2020

Status Report



Wastewater Treatment Plant Paide



In the frame of





On behalf of



August 2018




PAC retention by Mecana pile cloth filter

Piloting at Viikinmäki WWTP
Part of the CWPharma project




PAC retention by microsieve

Piloting at Viikinmäki WWTP
Part of the CWPharma project




Water Research
Volume 186, 1 November 2020, 116389




Concentration dependent degradation of pharmaceuticals in WWTP effluent by biofilm reactors

Sif B. Svendsen ^{1,2}, Haitham El-talhi ³



Science of The Total Environment
Volume 731, 20 August 2020, 139604




Ozone dose dependent formation and removal of ozonation products of pharmaceuticals in pilot and full-scale municipal wastewater treatment plants

Suman Kharel ¹, Michael Staggs ², Ulf Mische ³, Maja Ekblad ⁴, Michael Cimbritz ⁵, Per Falås ⁶, Josefine Nilsson ⁶, Robert Selién ⁶, Kai Bester ^{1,5,8}

WWTPs with (planned) AWT in Germany and Switzerland


WWTPs with AWT in Germany

n = 96 (30 in operation, 66 in planning/construction)



WWTPs with AWT in Switzerland

n = 48 (12 in operation, 36 in planning/construction)



Full bars = in operation, shaded bars = in planning/construction

Data based on: Metzger, S., Barjenbruch, M., Beier, S., Miehe, U., & Nafu, I. (2020). Statusbericht „Spurenstoffentfernung auf kommunalen Kläranlagen in Deutschland“. *Korrespondenz Abwasser, Abfall*, 67.

Data based on: <https://micropoll.ch/Mediathek/liste-der-aras-mit-mv-stufe/>, status 02/09/2020

Summary

Know your water quality:

- Dosage of ozone and PAC has to be adapted to the organic background of the wastewater (DOC)
- Nitrite causes additional ozone demand ($3.4 \text{ mgO}_3/\text{mg-N!}$)
- Be aware of bromide levels when you consider ozonation (sea side WWTPs!)

Monitor your process:

- API elimination can be monitored by using surrogate parameters (e.g. UVA_{254} reduction) – online or offline.
- Same surrogate parameters can also be used for process control to adapt the dosage, if necessary
- Ecotoxicological tests (e.g. mutagenicity, estrogenicity, *Aliivibrio fischeri* bioluminescence inhibition) can be used to evaluate the impact of the different treatment stages (enrichment factors 100 – 1000)



Project partners



EUROPEAN
REGIONAL
DEVELOPMENT
FUND

